{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:52:17Z","timestamp":1792821137352,"version":"4.5.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\u2003<\/jats:title>\n                    <jats:p>With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents. We compared CV risk among patients with gout who initiated allopurinol vs. benzbromarone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results\u2003<\/jats:title>\n                    <jats:p>Using the Korean National Health Insurance claims data (2002\u201317), we conducted a cohort study of 124 434 gout patients who initiated either allopurinol (n\u2009=\u2009103 695) or benzbromarone (n\u2009=\u200920 739), matched on propensity score at a 5:1 ratio. The primary outcome was a composite CV endpoint of myocardial infarction, stroke\/transient ischaemic attack, or coronary revascularization. To account for competing risk of death, we used cause-specific hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the outcomes comparing allopurinol initiators with benzbromarone. Over a mean follow-up of 1.16\u2009years, 2258 patients developed a composite CV event. The incidence rate of the composite CV event was higher in allopurinol initiators (1.81 per 100 person-years) than benzbromarone (1.61 per 100 person-years) with a HR of 1.22 (95% CI 1.05\u20131.41). The HR for all-cause mortality was 1.66 (95% CI 1.43\u20131.93) among allopurinol initiators compared with benzbromarone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion\u2003<\/jats:title>\n                    <jats:p>In this large population-based cohort of gout patients, allopurinol was associated with an increased risk of composite CV events and all-cause mortality compared to benzbromarone. Benzbromarone may reduce CV risk and mortality in patients with gout, although more studies are necessary to confirm our findings and to advance our understanding of the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab619","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T07:44:26Z","timestamp":1631087066000},"page":"4578-4588","source":"Crossref","is-referenced-by-count":63,"title":["Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital , 166 Gumiro Bundang-gu, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-4182","authenticated-orcid":false,"given":"Eun Hye","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chung-Ang University, School of Medicine, Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital , 166 Gumiro Bundang-gu, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-5125","authenticated-orcid":false,"given":"Jung Soo","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chung-Ang University, School of Medicine, Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2022102614541668600_ehab619-B1","year":"2021"},{"key":"2022102614541668600_ehab619-B2","volume-title":"Cardiovascular Disease Statistics","author":"Townsend","year":"2015"},{"key":"2022102614541668600_ehab619-B3","first-page":"462"},{"key":"2022102614541668600_ehab619-B4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/CIRCULATIONAHA.119.041653","article-title":"It is time for reducing global cardiovascular mortality","volume":"140","author":"Colantonio","year":"2019","journal-title":"Circulation"},{"key":"2022102614541668600_ehab619-B5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2022102614541668600_ehab619-B6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022102614541668600_ehab619-B7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: what should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2022102614541668600_ehab619-B8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"2022102614541668600_ehab619-B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11926-019-0843-8","article-title":"Cardiovascular safety of urate lowering therapies","volume":"21","author":"Kang","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2022102614541668600_ehab619-B10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/eurheartj\/ehab276","article-title":"Coronary artery disease: 'gout' in the artery?","volume":"42","author":"Strandberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614541668600_ehab619-B11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614541668600_ehab619-B12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"2022102614541668600_ehab619-B13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehz199","article-title":"Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?","volume":"40","author":"Messerlim","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614541668600_ehab619-B14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102614541668600_ehab619-B15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2022102614541668600_ehab619-B16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/15257770.2011.622732","article-title":"Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease","volume":"30","author":"Fujimori","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2022102614541668600_ehab619-B17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022102614541668600_ehab619-B18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"key":"2022102614541668600_ehab619-B19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","article-title":"Benzbromarone in the treatment of gout","volume":"59","author":"Azevedo","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2022102614541668600_ehab619-B20","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s10067-018-4306-9","article-title":"International position paper on the appropriate use of uricosurics with the introduction of lesinurad","volume":"37","author":"Jansen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022102614541668600_ehab619-B21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022102614541668600_ehab619-B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2022102614541668600_ehab619-B23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CP201425","article-title":"Serum CRP in patients with gout and effects of benzbromarone","volume":"49","author":"Okuda","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2022102614541668600_ehab619-B24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.b14-00514","article-title":"Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment","volume":"38","author":"Kadowaki","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2022102614541668600_ehab619-B25","doi-asserted-by":"crossref","first-page":"7635274","DOI":"10.1155\/2018\/7635274","article-title":"Benzbromarone attenuates oxidative stress in angiotensin II- and salt-induced hypertensive model rats","volume":"2018","author":"Muraya","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"2022102614541668600_ehab619-B26","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1038\/s41467-019-12226-1","article-title":"The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"2022102614541668600_ehab619-B27","doi-asserted-by":"crossref","first-page":"1800965","DOI":"10.1183\/13993003.00965-2018","article-title":"Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension","volume":"53","author":"Papp","year":"2019","journal-title":"Eur Respir J"},{"key":"2022102614541668600_ehab619-B28","first-page":"799","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2022102614541668600_ehab619-B29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"key":"2022102614541668600_ehab619-B30","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/pds.1821","article-title":"An algorithm to identify incident myocardial infarction using Medicaid data","volume":"18","author":"Choma","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102614541668600_ehab619-B31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pds.2312","article-title":"A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data","volume":"21","author":"Andrade","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102614541668600_ehab619-B32","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2022102614541668600_ehab619-B33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2022102614541668600_ehab619-B34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2022102614541668600_ehab619-B35","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2022102614541668600_ehab619-B36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4419-6646-9","volume-title":"Survival Analysis: A Self, Learning Text","author":"Kleinbaum","year":"2012","edition":"3rd ed"},{"key":"2022102614541668600_ehab619-B37","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"2022102614541668600_ehab619-B38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"key":"2022102614541668600_ehab619-B39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0006-291X(87)91112-0","article-title":"Role of xanthine oxidase inhibitor as free radical scavenger: a novel mechanism of action of allopurinol and oxypurinol in myocardial salvage","volume":"148","author":"Das","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"2022102614541668600_ehab619-B40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","article-title":"Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia","volume":"63","author":"Takir","year":"2015","journal-title":"J Investig Med"},{"key":"2022102614541668600_ehab619-B41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022102614541668600_ehab619-B42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022102614541668600_ehab619-B43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022102614541668600_ehab619-B44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2022102614541668600_ehab619-B45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003495-197714050-00002","article-title":"Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia","volume":"14","author":"Heel","year":"1977","journal-title":"Drugs"},{"key":"2022102614541668600_ehab619-B46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0002-9343(55)90241-2","article-title":"Diuretic action of benemid; its effect upon the urinary excretion of sodium, chloride, potassium and water in edematous subjects","volume":"18","author":"Bronsky","year":"1955","journal-title":"Am J Med"},{"key":"2022102614541668600_ehab619-B47","doi-asserted-by":"crossref","first-page":"e007148","DOI":"10.1161\/JAHA.117.007148","article-title":"Probenecid improves cardiac function in patients with heart failure with reduced ejection fraction in vivo and cardiomyocyte calcium sensitivity in vitro","volume":"7","author":"Robbins","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022102614541668600_ehab619-B48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphys.2018.00849","article-title":"Probenecid pre-treatment downregulates the kidney Cl\u2212\/HCO3\u2212 exchanger (pendrin) and potentiates hydrochlorothiazide-induced diuresis","volume":"9","author":"Barone","year":"2018","journal-title":"Front Physiol"},{"key":"2022102614541668600_ehab619-B49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.117.10251","article-title":"Probenecid inhibits \u03b1-adrenergic receptor-mediated vasoconstriction in the human leg vasculature","volume":"71","author":"Nyberg","year":"2018","journal-title":"Hypertension"},{"key":"2022102614541668600_ehab619-B50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.numecd.2014.08.006","article-title":"Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling","volume":"25","author":"Liang","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022102614541668600_ehab619-B51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000087713","article-title":"Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter","volume":"25","author":"Kang","year":"2005","journal-title":"Am J Nephrol"},{"key":"2022102614541668600_ehab619-B52","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102614541668600_ehab619-B53","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"key":"2022102614541668600_ehab619-B54","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"key":"2022102614541668600_ehab619-B55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2215\/CJN.10771016","article-title":"Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial","volume":"12","author":"McMullan","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102614541668600_ehab619-B56","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/biom10040576","article-title":"Uric acid has direct proinflammatory effects on human macrophages by increasing proinflammatory mediators and bacterial phagocytosis probably via URAT1","volume":"10","author":"Mart\u00ednez-Reyes","year":"2020","journal-title":"Biomolecules"},{"key":"2022102614541668600_ehab619-B57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/annrheumdis-2014-206564","article-title":"Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra","volume":"75","author":"Cri\u0219an","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022102614541668600_ehab619-B58","doi-asserted-by":"crossref","first-page":"C584","DOI":"10.1152\/ajpcell.00600.2006","article-title":"Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative\/nitrosative stress","volume":"293","author":"Sautin","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022102614541668600_ehab619-B59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2013.04.027","article-title":"Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic \u03b2 cells","volume":"375","author":"Zhang","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"2022102614541668600_ehab619-B60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/44\/4578\/46645648\/ehab619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/44\/4578\/46645648\/ehab619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T15:57:43Z","timestamp":1673193463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/44\/4578\/6368678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":60,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2021,9,11]]},"published-print":{"date-parts":[[2021,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab619","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,21]]},"published":{"date-parts":[[2021,9,11]]}}}